Publications by authors named "R E Hanada"
Phase 1 Mass Balance Study of Pizuglanstat: An Investigational Hematopoietic Prostaglandin D Synthase Inhibitor.
Clin Pharmacol Drug Dev
January 2025
Pizuglanstat is a novel hematopoietic prostaglandin D synthase inhibitor and investigational treatment for Duchenne muscular dystrophy. This Phase 1 mass balance study aimed to characterize the absorption, metabolism, and excretion of carbon-14 (C)-labeled pizuglanstat in healthy adults (ClinicalTrials.gov, NCT04825431).
View Article and Find Full Text PDFAmazonian Dark Earths (ADEs) are fertile soils from the Amazon rainforest that harbor microorganisms with biotechnological potential. This study aimed to investigate the individual and potential synergistic effects of a 2% portion of ADEs and Urochloa brizantha cv. Marandu roots (Brazil's most common grass species used for pastures) on soil prokaryotic communities and overall soil attributes in degraded soil.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to assess the safety and pharmacokinetics of a new drug, BI 1291583, which inhibits cathepsin C to potentially reduce inflammation in bronchiectasis patients.
- Conducted as a randomized, double-blind, placebo-controlled trial, it involved healthy Japanese males and evaluated both single and multiple doses for any related adverse events and drug absorption levels.
- Results indicated that the drug was safe and well-tolerated, with no serious side effects and an adequate benefit-risk ratio, suggesting it can be used in future clinical trials involving bronchiectasis patients without needing dose adjustments.
Article Synopsis
- * A retrospective analysis was conducted on 56 patients with gastroenterological diseases who were referred from a regional hospital to a tertiary facility, primarily using a cloud-based image-sharing system over three years.
- * The study found that most patients (80.4%) had hepatobiliary pancreatic issues, with swift referral processes leading to timely treatments; however, many patients faced waiting lists, highlighting the benefits of remote imaging for efficiency in care.
Background: Failure-free survival (FFS) rates of low-risk patients with rhabdomyosarcoma improved in Intergroup Rhabdomyosarcoma Study IV after the escalation of cyclophosphamide total dose to 26.4 g/m. However, this dose may increase the risk of adverse events, including infertility, in some patients.
View Article and Find Full Text PDF